MX2021009142A - Inhibidores topicos de fosfoinositol 3-cinasas. - Google Patents

Inhibidores topicos de fosfoinositol 3-cinasas.

Info

Publication number
MX2021009142A
MX2021009142A MX2021009142A MX2021009142A MX2021009142A MX 2021009142 A MX2021009142 A MX 2021009142A MX 2021009142 A MX2021009142 A MX 2021009142A MX 2021009142 A MX2021009142 A MX 2021009142A MX 2021009142 A MX2021009142 A MX 2021009142A
Authority
MX
Mexico
Prior art keywords
sup
topical
phosphoinositide
kinase inhibitors
compounds
Prior art date
Application number
MX2021009142A
Other languages
English (en)
Inventor
Agis Kydonieus
Hock S Tan
Ahmed F Abdel-Magid
Thomas Rossi
Original Assignee
Venthera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venthera Inc filed Critical Venthera Inc
Publication of MX2021009142A publication Critical patent/MX2021009142A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona compuestos y formulaciones tópicas que incluyen los compuestos para el tratamiento de malformaciones vasculares, en donde los compuestos son de acuerdo con la fórmula (I): (ver Fórmula) en donde el subíndice m, L1, R1 y L1-R1 son como se describen en la presente.
MX2021009142A 2019-02-06 2020-02-05 Inhibidores topicos de fosfoinositol 3-cinasas. MX2021009142A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802093P 2019-02-06 2019-02-06
US202062958049P 2020-01-07 2020-01-07
PCT/US2020/016876 WO2020163525A1 (en) 2019-02-06 2020-02-05 Topical phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2021009142A true MX2021009142A (es) 2021-10-13

Family

ID=71835949

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009142A MX2021009142A (es) 2019-02-06 2020-02-05 Inhibidores topicos de fosfoinositol 3-cinasas.

Country Status (14)

Country Link
US (2) US11661429B2 (es)
EP (1) EP3920911A4 (es)
JP (1) JP2022519317A (es)
KR (1) KR20210124310A (es)
CN (1) CN114072144A (es)
AU (1) AU2020219065A1 (es)
BR (1) BR112021015353A2 (es)
CA (1) CA3127686A1 (es)
IL (1) IL285020A (es)
MA (1) MA54907A (es)
MX (1) MX2021009142A (es)
SG (1) SG11202108274SA (es)
TW (1) TW202045513A (es)
WO (1) WO2020163525A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127686A1 (en) 2019-02-06 2020-08-13 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors
CA3187759A1 (en) * 2020-08-04 2022-02-10 Agis Kydonieus Formulations of phosphoinositide 3-kinase inhibitors
IL311242A (en) * 2021-09-15 2024-05-01 Dermbiont Inc Compositions and formulations for topical use of an AKT inhibitor for the prevention, treatment and improvement of skin diseases, conditions and disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3602519B2 (ja) 2002-07-12 2004-12-15 コナミ株式会社 ビデオゲーム装置、画像処理方法及びプログラム
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
US20080199449A1 (en) 2005-08-12 2008-08-21 The General Hospital Corporation Methods and Compositions for Use in Treating Vascular Diseases and Conditions
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
MX2011007326A (es) * 2009-01-08 2011-10-19 Curis Inc Inhibidores de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
WO2011070499A1 (en) 2009-12-11 2011-06-16 Wyeth Llc Phosphatidylinositol-3-kinase pathway biomarkers
CN102268014B (zh) 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
SI2627316T1 (sl) 2010-10-13 2019-06-28 Medivir Ab Farmacevtska formulacija za zaviralce histonske deacetilaze
RU2014107713A (ru) 2011-07-28 2015-09-10 Дженентек, Инк Модель рака молочной железы у животных, кроме человека, с активируемым pik3ca h1047r
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
KR101915942B1 (ko) 2012-06-08 2018-11-06 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
AU2016265844B2 (en) 2015-05-15 2021-02-11 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
JP7051693B2 (ja) 2016-02-19 2022-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＰＩＫ３ＣＡ関連過成長症候群（ＰＲＯＳ ＣＬＯＶａＳ症候群）の処置に使用するためのＢＹＬ７１９（アルペリシブ）
US20170340649A1 (en) 2016-05-30 2017-11-30 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
KR102358377B1 (ko) 2016-12-28 2022-02-03 히사미쓰 세이야꾸 가부시키가이샤 첩부제
CA3127686A1 (en) 2019-02-06 2020-08-13 Venthera, Inc. Topical phosphoinositide 3-kinase inhibitors

Also Published As

Publication number Publication date
US20230416269A1 (en) 2023-12-28
EP3920911A4 (en) 2023-03-08
US20200247816A1 (en) 2020-08-06
SG11202108274SA (en) 2021-08-30
CN114072144A (zh) 2022-02-18
BR112021015353A2 (pt) 2021-10-05
WO2020163525A1 (en) 2020-08-13
MA54907A (fr) 2022-05-11
TW202045513A (zh) 2020-12-16
US11661429B2 (en) 2023-05-30
JP2022519317A (ja) 2022-03-22
IL285020A (en) 2021-09-30
KR20210124310A (ko) 2021-10-14
EP3920911A1 (en) 2021-12-15
CA3127686A1 (en) 2020-08-13
AU2020219065A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EA202091267A1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
CR20200578A (es) Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2012002641A (es) Inhibidores de cinasa janus (jak).
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
AU2020231934A8 (en) Compounds useful in HIV therapy
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MX2020012760A (es) Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2.
MX2023012907A (es) Inhibidores de inflamasoma proteina 3 que contiene dominios de pirina (nlrp3).
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
EP4316504A3 (en) Compounds
MX2022016357A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.